Zogenix Company Profile (NASDAQ:ZGNX)

About Zogenix

Zogenix logoZogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company's areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ZGNX
  • CUSIP: 98978L10
Key Metrics:
  • Previous Close: $10.45
  • 50 Day Moving Average: $10.02
  • 200 Day Moving Average: $10.25
  • 52-Week Range: $7.33 - $13.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.13
  • P/E Growth: -0.15
  • Market Cap: $252.86M
  • Outstanding Shares: 24,790,000
  • Beta: 1.51
Profitability:
  • Net Margins: -229.93%
  • Return on Equity: -38.11%
  • Return on Assets: -22.31%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 9.58%
  • Quick Ratio: 8.91%
Additional Links:
Companies Related to Zogenix:

Analyst Ratings

Consensus Ratings for Zogenix (NASDAQ:ZGNX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.33 (138.56% upside)

Analysts' Ratings History for Zogenix (NASDAQ:ZGNX)
Show:
DateFirmActionRatingPrice TargetDetails
2/14/2017AegisInitiated CoverageBuy$28.00View Rating Details
10/4/2016Leerink SwannReiterated RatingOutperform$17.00View Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00View Rating Details
11/10/2015William BlairInitiated CoverageHoldView Rating Details
10/21/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$23.00View Rating Details
4/21/2015Piper Jaffray CompaniesInitiated CoverageOverweight$2.50View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Zogenix (NASDAQ:ZGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zogenix (NASDAQ:ZGNX)
Current Year EPS Consensus Estimate: $-2.71 EPS
Next Year EPS Consensus Estimate: $-3.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.72)($0.72)($0.72)
Q2 20162($0.88)($0.81)($0.85)
Q3 20163($1.00)($0.83)($0.94)
Q4 20163($1.13)($0.78)($1.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zogenix (NASDAQ:ZGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zogenix (NASDAQ:ZGNX)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 84.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.00View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.00View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zogenix (NASDAQ:ZGNX)
DateHeadline
News IconThe Bears And Bulls Square Off On Zogenix, Inc. (ZGNX) - NY Stock News (NASDAQ:ZGNX)
nystocknews.com - February 17 at 5:22 PM
finance.yahoo.com logoZogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference (NASDAQ:ZGNX)
finance.yahoo.com - February 17 at 9:25 AM
streetinsider.com logoAegis Capital Reiterates Buy Rating and $28 PT on Zogenix (ZGNX ... - StreetInsider.com (NASDAQ:ZGNX)
www.streetinsider.com - February 15 at 7:04 AM
News IconZogenix, Inc. (ZGNX) stock coverage initiated with “Buy” in note to ... - The Ledger Gazette (NASDAQ:ZGNX)
ledgergazette.com - February 15 at 7:04 AM
streetinsider.com logoZogenix (ZGNX) Begins Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet (NASDAQ:ZGNX)
www.streetinsider.com - February 14 at 7:18 AM
finance.yahoo.com logoZogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome (NASDAQ:ZGNX)
finance.yahoo.com - February 14 at 7:18 AM
feeds.benzinga.com logoZogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:ZGNX)
feeds.benzinga.com - February 8 at 8:54 AM
News IconZogenix, Inc. (NASDAQ: ZGNX) Receives Patent for ZX008 in the Treatment of Dravet Syndrome (NASDAQ:ZGNX)
blog.qualitystocks.net - February 2 at 7:00 AM
finance.yahoo.com logo8:03 am Zogenix announces USPTO issuance for a patent covering claims related to a method for the adjunctive treatment of seizures associated with Dravet syndrome with ZX008; patent is expected to provide protection of the associated claims (NASDAQ:ZGNX)
finance.yahoo.com - January 31 at 8:17 AM
feeds.benzinga.com logoZogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome (NASDAQ:ZGNX)
feeds.benzinga.com - January 30 at 8:12 AM
News IconInvestor Technical Review for Zogenix Inc. (ZGNX) - Rives Journal (NASDAQ:ZGNX)
rivesjournal.com - January 29 at 7:21 AM
News IconIs There Inherent Value in Zogenix, Inc. (NASDAQ:ZGNX)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 27 at 9:28 PM
News IconZogenix, Inc. (NASDAQ:ZGNX) Quarterly EPS Projection At $-0.84 - Stock Observer (NASDAQ:ZGNX)
www.thestockobserver.com - January 27 at 4:19 PM
News IconNarrowing in on Chart Levels for Zogenix Inc. (ZGNX) - Sherwood Daily (NASDAQ:ZGNX)
sherwooddaily.com - January 27 at 6:57 AM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on Zogenix, Inc. (NASDAQ:ZGNX) - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 27 at 6:57 AM
News IconZogenix Inc ZGNX Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 19122016] Prices from USD $250 (NASDAQ:ZGNX)
www.bioportfolio.com - January 26 at 6:38 AM
News IconAnalysts Pounding The Pavement on Zogenix, Inc. (NASDAQ:ZGNX): Consensus Update - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 24 at 5:35 AM
News IconAmplified Volatility Spotted in Shares of Zogenix, Inc. (NASDAQ:ZGNX) - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 21 at 6:16 AM
News IconAnalysts Pull Back the Curtain on Zogenix, Inc. (NASDAQ:ZGNX ... - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 21 at 6:16 AM
News IconTechnical Watch on These Shares: Zogenix Inc. (ZGNX) - Rives Journal (NASDAQ:ZGNX)
rivesjournal.com - January 19 at 8:17 AM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Zogenix, Inc. (NASDAQ:ZGNX) - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 18 at 6:34 AM
News IconEarnings Fever Sweeping In, What Are Analysts Expecting From Zogenix, Inc. (NASDAQ:ZGNX)? - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 18 at 6:34 AM
News IconWill The Needle Move For Zogenix, Inc. (NASDAQ:ZGNX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 18 at 6:34 AM
News IconPrimed For An Earnings Beat? Sell-side Chimes in on Zogenix, Inc. (NASDAQ:ZGNX) Stock - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 13 at 8:34 PM
News IconEPS Of Zogenix, Inc. (NASDAQ:ZGNX) At $-0.84 - Stock Observer (NASDAQ:ZGNX)
www.thestockobserver.com - January 13 at 3:32 PM
News IconNews Impact Score Of Zogenix, Inc. (NASDAQ:ZGNX) Set At 33 - Stock Observer (NASDAQ:ZGNX)
www.thestockobserver.com - January 13 at 7:41 AM
News IconWall Street and Armchair Analysts Weigh in on Zogenix, Inc. (NASDAQ:ZGNX) Heading Into The New Year - Wall Street Beacon (NASDAQ:ZGNX)
wsbeacon.com - January 13 at 7:41 AM
marketexclusive.com logoZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NASDAQ:ZGNX)
marketexclusive.com - January 9 at 3:28 PM
biz.yahoo.com logoZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial (NASDAQ:ZGNX)
biz.yahoo.com - January 9 at 3:28 PM
News IconZogenix Inc ZGNX Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:ZGNX)
www.bioportfolio.com - January 7 at 6:37 AM
biz.yahoo.com logoZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ZGNX)
us.rd.yahoo.com - January 7 at 6:37 AM
streetinsider.com logoZogenix (ZGNX) Reports CFO Transition - StreetInsider.com - StreetInsider.com (NASDAQ:ZGNX)
www.streetinsider.com - January 6 at 6:45 AM
publicnow.com logoZogenix Announces CFO Transition (NASDAQ:ZGNX)
www.publicnow.com - January 6 at 6:45 AM
News IconZogenix, Inc. (NASDAQ:ZGNX) EPS At $-0.84 - Stock Observer (NASDAQ:ZGNX)
www.thestockobserver.com - December 31 at 2:38 AM
capitalcube.com logoETFs with exposure to Zogenix, Inc. : December 21, 2016 (NASDAQ:ZGNX)
www.capitalcube.com - December 22 at 6:15 AM
News IconReady for an Upsurge? Analysts Chime in on Zogenix, Inc. (NASDAQ:ZGNX) - Prospect Journal (NASDAQ:ZGNX)
prospectjournal.com - December 20 at 8:52 AM
investornewswire.com logoSentiments And Ratings Alert: Zogenix, Inc. (NASDAQ:ZGNX) - Investor Newswire (NASDAQ:ZGNX)
www.investornewswire.com - December 19 at 3:45 PM
News IconWatching the Levels: Zogenix, Inc. (NASDAQ:ZGNX) - OIB News (NASDAQ:ZGNX)
oibnews.com - December 19 at 3:45 PM
News IconNarrowing in on the Numbers for Zogenix, Inc. (NASDAQ:ZGNX) - Liberty News (NASDAQ:ZGNX)
libertynewsrecord.com - December 19 at 2:30 AM
News IconNews Impact Score Of Zogenix, Inc. (NASDAQ:ZGNX) At 100 - Stock Observer (NASDAQ:ZGNX)
www.thestockobserver.com - December 14 at 3:55 PM
News IconWatching the Numbers for Zogenix, Inc. (NASDAQ:ZGNX) - Liberty News (NASDAQ:ZGNX)
libertynewsrecord.com - December 8 at 3:20 PM
fool.com logoIs Zogenix Stock Still a Buy After Soaring in November? (NASDAQ:ZGNX)
www.fool.com - December 8 at 10:29 AM
News IconInvestor Update: Looking at Shares of Zogenix, Inc. (NASDAQ:ZGNX) - Liberty News (NASDAQ:ZGNX)
libertynewsrecord.com - December 6 at 8:00 AM
marketexclusive.com logoZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Other Events - Market Exclusive (NASDAQ:ZGNX)
marketexclusive.com - December 6 at 8:00 AM
biz.yahoo.com logoZOGENIX, INC. Files SEC form 8-K, Other Events (NASDAQ:ZGNX)
biz.yahoo.com - December 6 at 8:00 AM
us.rd.yahoo.com logoZogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome (NASDAQ:ZGNX)
us.rd.yahoo.com - December 5 at 8:00 PM
us.rd.yahoo.com logo8:07 am Zogenix announces new data demonstrating effectiveness and cardiovascular-related safety for patients treated with ZX008 at the AES meeting (NASDAQ:ZGNX)
us.rd.yahoo.com - December 5 at 8:00 PM
News IconInvestor Focus: Watching Shares of Zogenix, Inc. (NASDAQ:ZGNX) - Marion Business Daily (NASDAQ:ZGNX)
marionbusinessdaily.com - December 4 at 7:36 PM
News IconZogenix, Inc. (ZGNX) Develops Orphan Drug for Dravet Syndrome Epilepsy (NASDAQ:ZGNX)
missionir.com - December 3 at 8:37 AM
News IconCompany in Focus: Zogenix, Inc. (NASDAQ:ZGNX) - OIB News (NASDAQ:ZGNX)
oibnews.com - December 2 at 9:09 PM

Social

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Where is Zogenix's stock going? Where will Zogenix's stock price be in 2017?

3 analysts have issued 1 year price objectives for Zogenix's shares. Their predictions range from $17.00 to $28.00. On average, they expect Zogenix's stock price to reach $24.33 in the next year.

When will Zogenix announce their earnings?

Zogenix is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:

  • Aegis analysts commented, "adjunctive anti-epileptic therapy."Yang comments, "Study 1504 - a two cohort study to assess ZX008 as an adjunctive antiepileptic therapy. Designed as a multi-center study, 1504 is portioned into two cohorts that are a part of the phase III program for ZX008 in Dravet Syndrome. The first cohort assessed the pharmacokinetics and safety profile of ZX008 (fenfluramine hydrochloride), valproate, and clobazam when administered with stiripentol. In assessing these two aspects, cohort 1 served its primary purpose - identify the appropriate dosage of ZX008 to be used in the second cohort of the trial (0.5 mg/kg/day). Cohort 2 is designed as a double-blind, placebocontrolled trial randomizing 70 patients 1:1 (ZX008:placebo) after a 6 week baseline observation period. After a 3 week titration period, patients will receive either 0.5 mg/kg/day of ZX008 or equivalent placebo before being assessed at 12 weeks. The primary endpoint for cohort 2 is change from baseline in frequency of convulsive seizures, the same as study 1501 and 1502. All patients enrolled in the "stiripentol incomplete responder" trial will remain on their stable stiripentol drug regimen in addition to receiving either ZX008 or placebo." (2/14/2017)
  • According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (1/18/2017)

Who owns Zogenix stock?

Zogenix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (7.16%), Federated Investors Inc. PA (5.99%), Broadfin Capital LLC (3.09%), Perceptive Advisors LLC (3.04%), Franklin Resources Inc. (2.57%) and State Street Corp (1.69%).

Who sold Zogenix stock? Who is selling Zogenix stock?

Zogenix's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Broadfin Capital LLC and State Street Corp.

Who bought Zogenix stock? Who is buying Zogenix stock?

Zogenix's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Federated Investors Inc. PA, City Financial Investment Co Ltd, Dimensional Fund Advisors LP and A.R.T. Advisors LLC.

How do I buy Zogenix stock?

Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zogenix stock cost?

One share of Zogenix stock can currently be purchased for approximately $10.20.

Zogenix (NASDAQ:ZGNX) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Earnings History Chart

Earnings by Quarter for Zogenix (NASDAQ:ZGNX)

Dividend History Chart

Dividend Payments by Quarter for Zogenix (NASDAQ:ZGNX)

Last Updated on 2/20/2017 by MarketBeat.com Staff